Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 3 - Drugs for disorders of the metabolism
Patents for A61P 3 - Drugs for disorders of the metabolism (129,789)
05/2005
05/25/2005EP1531815A1 Glucokinase activators
05/25/2005EP1531812A1 Fused heteroaryl derivatives for use as p38 kinase inhibitors in the treatment of i.a. rheumatoid arthristis
05/25/2005EP1531810A2 Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method
05/25/2005EP1531807A1 Bazedoxifene treatment regimens
05/25/2005EP1531799A1 Nanoparticulate formulations comprising hmg coa reductase inhibitor derivatives ("statins"), novel combinations thereof as well as manufacturing of these pharmaceutical compositions
05/25/2005EP1531793A1 Ophtalmic ointment composition comprising a drug, an ointment base and a solubiling/dispersing agent
05/25/2005EP1432682B1 Process for the preparation of repaglinide
05/25/2005EP1365762A4 Method for increasing leptin levels using nicotinic acid compounds
05/25/2005EP1286673B1 Ligands of integrin receptors
05/25/2005EP1213287B1 Substituted benzylthiazolidine-2,4-dione derivatives
05/25/2005EP1207158B1 Substituted benzylthiazolidine-2,4-dione derivatives
05/25/2005EP1183247B1 Polycyclic thiazole systems and their utilization as anorectics
05/25/2005EP1163335B1 MATERIALS AND METHODS RELATING TO MODULATION OF p66 EXPRESSION
05/25/2005EP1054993B1 PROCESS FOR THE OBTAINING OF HMG-CoA REDUCTASE INHIBITORS OF HIGH PURITY
05/25/2005EP1033132B1 Rapidly soluble drug composition comprising micronized as-3201
05/25/2005EP0814796B1 Use of a r-nsaid in a protective composition for the treatment of colorectal cancer
05/25/2005CN1620510A Cytokine protein family
05/25/2005CN1620505A Pim-3 kinase as a target for type 2 diabetes mellitus
05/25/2005CN1620467A Secreted protein
05/25/2005CN1620466A Cystine-knot fold protein
05/25/2005CN1620461A 2-amino-propanol derivatives
05/25/2005CN1620457A Tetracyclic heterocompounds as estrogen receptor modulators
05/25/2005CN1620453A Thiazolidinedione derivative and its use as antidiabetic
05/25/2005CN1620452A 3, 4-dihydro-1h-isoquinoloin-2-yl-derivatives
05/25/2005CN1620439A Pancreatic lipase inhibitor compounds, their synthesis and use
05/25/2005CN1620438A 5, 6-diaryl-pyrazine-2-amide derivatives as CBI antagonists
05/25/2005CN1620434A Pyrrolidine-2-ones as factor Xa inhibitors
05/25/2005CN1620433A Pyrrolidine derivatives as inhibitors of endothelin-converting enzyme
05/25/2005CN1620431A (20s)-1alpha-hydroxy-2-methylene-19-nor-bishomopregnacalciferol and its uses
05/25/2005CN1620430A 3-phenyl-2-arylalkylthiopropionic acid derivatives as selective agonists of PPAR-alpha
05/25/2005CN1620429A Derivatives of alpha-phenylthiocarboxylic and g(a)-phenyloxy-carboxylic acids useful for the treatment of diseases responding to PPAR alpha activation
05/25/2005CN1620424A Compounds for the treatment of inflammatory disorders
05/25/2005CN1620423A Substituted phenypropionic acid derivatives as agonists to human peroxisome proliferator-activated receptor alpha (PPAR)
05/25/2005CN1620422A Substituted phenypropionic acid derivatives as agonists to human peroxisome proliferator-activated receptor alpha (PPAR)
05/25/2005CN1620419A 1-amino-alkylcyclohexanes as 5-HT3 and neuronal nicotinic receptor antagonists
05/25/2005CN1620414A 维生素d类似物 Vitamin d analogues
05/25/2005CN1620413A Method for stabilizing reduced coenzyme Q 10 and composition therefor
05/25/2005CN1620325A Superoxide dismutase mimics for the treatment of ocular disorders and diseases
05/25/2005CN1620301A Pharmaceutically acceptable phosphate-glycerol carrying bodies
05/25/2005CN1620299A Alpha-hydroxy-2-methylene-10-nor-pregnacalciferol and its uses
05/25/2005CN1620294A Pyrimidine A2b selective antagonist compounds, their synthesis and use
05/25/2005CN1620287A Composition for pharmaceutical or dietetic use for combating hair loss
05/25/2005CN1620281A Formulation & dosage form for the controlled delivery of therapeutic agents
05/25/2005CN1620257A Matrix-forming composition containing pectin
05/25/2005CN1620255A Protein-containing foodstuff comprising a coss-linking enzyme and a hydrocolloid
05/25/2005CN1620251A Cultured and encapsulated pancreatic stem cells
05/25/2005CN1619312A Specific markers for metabolic syndrome
05/25/2005CN1618958A Human cholesteryl ester synthetase-2c and its coding sequence
05/25/2005CN1618957A Human cholesteryl ester synthetase-2b and its coding sequence
05/25/2005CN1618446A Medicine for treating diabetes, and its prepn. method
05/25/2005CN1618441A Medicinal composition for regulating blood fat, prepn. method and use thereof
05/25/2005CN1618435A Oral liquor for promoting-blood circulation and removing blood stasis contg. Radix astragali and ginseng
05/25/2005CN1618433A Medicine prepared with inosine and fructose composition
05/25/2005CN1618425A Composition contg. theaflavin and its derivatives, prepn. method and application thereof
05/25/2005CN1618335A Health-care food with assistant functions of decreasing blood-sugar and blood-fat, and its prepn. method
05/25/2005CN1203083C Rhizoma anemarrhenae extract and preparation process
05/25/2005CN1203070C Thrombin receptor antagonists
05/25/2005CN1203058C Piperidine derivatives and drugs containing these derivatives as active ingredient
05/25/2005CN1203047C Biaryl ether derivatives useful as monoamine reuptake inhibitors
05/25/2005CN1202862C Compsns. comprising comjugates of stable, active, human OB protein with antibody Fc chain and methods
05/25/2005CN1202847C Diabetes treating medicine
05/25/2005CN1202846C Process for preparing medicine for dredging meridian and reducing blood fat
05/25/2005CN1202823C Use of thiazolidinedione for preventing or retaining non-insulin-dependent diabets mellitus (NIDDM) attack
05/25/2005CN1202821C Use of thiazolidinedione for preventing or retaining non-insulin-dependent diabets mellitus (MIDDM) attack
05/25/2005CN1202816C Glimepiride dripping pills
05/25/2005CN1202812C Direct compression polymer tablet core
05/25/2005CN1202736C Method for administering viable microorganism composition for poultry
05/24/2005US6897319 Therapeutic drugs for treating central nervous system disorders
05/24/2005US6897318 Process for making substituted pyrazoles
05/24/2005US6897317 For therapy of arteriosclerosis and dyslipidaemias
05/24/2005US6897310 1,5-methylene-3-benzazepines used in treatment of neurological and psychological disorders,especially withdrawl from nicotine addiction
05/24/2005US6897235 Compositions useful for the treatment of pathologies responding to the activation of PPAR-γ receptor
05/24/2005US6897232 Activate soluble guanylate cyclase; for use treating cardiovascular disorders, erectile dysfunction, diabetes, and cirrhosis of the liver, kidney disorders, and learning disability
05/24/2005US6897231 Jun n- terminal kinase inhibitors such as 3-(4-methoxyphenyl)-1H-indazole
05/24/2005US6897222 Pyrido[2,1-a]isoquinoline derivatives
05/24/2005US6897210 Anticancer agents; antiarthritic agents
05/24/2005US6897198 Method of treatment with combinations of statin and aryl-substituted propanolamine derivatives
05/24/2005US6897050 Desaturase genes and their use
05/24/2005US6896912 Made of parasitic herb, and alder and/or schizandrae fructus, optionally supplemented with torilis fructus and/or polygalae japonica herba.
05/24/2005US6896901 Controlling or preventing cognitive dysfunction, hyperglycemia and some infective conditions of the skin in mammals by administering pharmaceutically acceptable effective amount of gugulipid
05/20/2005CA2487657A1 Specific markers for metabolic syndrome
05/19/2005WO2005045026A1 Insulin-expressing human islet cell lines capable of reversibly proliferating and use thereof
05/19/2005WO2005044814A1 BENZO [b][1,4] DIOXEPINE DERIVATIVES
05/19/2005WO2005044801A1 Pyridine carboxylic acid derivatives as glucokinase modulators
05/19/2005WO2005044290A1 Glucose absorption inhibitor and process for producing the same
05/19/2005WO2005014576A8 Isoquinolinone derivative, process for producing the same and use thereof
05/19/2005WO2004016764A3 eNOS MUTANTS USEFUL FOR GENE THERAPY
05/19/2005WO2003014703A3 Nucleic acids, polypeptides, single nucleotide polymorphisms and methods of use thereof
05/19/2005US20050108785 Using nuclear transplantation as tool in generating transgenic cells for treatment and prevention of liver, nervous system, cardiovascular and bone disorders; regenerative medicine
05/19/2005US20050107614 Reacting (S)-3-methyl-1-(2-piperidinophenyl)-1-butylamine with ethoxy-4-ethoxycarbonyl phenylacetic acid in the presence of pivaloyl chloride and a base, and removing the protecting group to obtain repaglinide
05/19/2005US20050107472 administering vitamin k derivatives for prophylaxis of neurodegenerative diseases associated with protein aggregation or neurofibrillary tangles
05/19/2005US20050107469 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs
05/19/2005US20050107457 Indazole derivatives as JNK inhibitors and compositions and methods related thereto
05/19/2005US20050107452 Black soybean polysaccharides
05/19/2005US20050107450 administering Peroxisome Proliferator Activated Receptors (PPAR-gamma) activators according to a dosage schedule which comprises a cycle of less than daily administration
05/19/2005US20050107449 Substituted thiazoles and oxazoles, e.g., 4-{1-[4-[2-(2-Chloro-6-fluoro-phenyl)-ethyl]-2-(4-trifluoromethyl-phenyl)-thiazol-5-yl]-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid; treating atherosclerosis and diabetes and creating Syndrome X
05/19/2005US20050107446 Two components mixture comprising a powder of atorvastatin with an alkalizing agent that forms a pH greater than 5 and a second component without the alkalizing agent; treating angina pectoris, hypertension, atherosclerosis
05/19/2005US20050107442 Compounds that modulate PPAR activity and methods of preparation
05/19/2005US20050107441 screening for drugs that alter glucose production by modulating gene expression and/or activity of the nuclear receptor short heterodimer partners, then using the drugs as hypoglycemic or hyperglycemic agents; antidiabetic agents; metabolic disorders
05/19/2005US20050107440 Rosiglitazone edisylates and their use as antidiabetics
1 ... 724 725 726 727 728 729 730 731 732 733 734 735 736 737 738 739 740 741 742 743 744 ... 1298